Overview
VITL provides an operating system for the cash-pay healthcare market by connecting medical practices with a network of verified 503A and 503B compounding pharmacies. Its core product is an e-prescribing marketplace where providers can compare real-time prices, order from multiple pharmacies in a single transaction, and track prescriptions from order to delivery. The platform replaces scattered pharmacy portals and manual workflows, reducing admin tasks and giving patients real-time order transparency with access to hard-to-find medications like peptides, GLP-1s, and HRT. Its goal is to close the infrastructure gap in cash-pay care by creating a competitive marketplace that makes specialized compounds more affordable and easier for clinics and patients to manage.
Work here?Claim your company
Simplify's take
What believers are saying
- March 26, 2026 Series A funded pharmacy expansion, interoperability, and hiring.
- Eight-figure ARR and 90% quarter-over-quarter order growth signal urgent customer pull.
- Cash-pay clinics keep expanding in med-spa, weight-loss, and concierge medicine markets.
What critics are saying
- FDA crackdowns on compounded semaglutide and tirzepatide hit VITL's pharmacy supply network.
- If 503B bulks-list restrictions finalize in late 2026, GLP-1 volumes shrink fast.
- Surescripts, Jane Software, and pharmacy portals can copy workflow features, compressing margins.
What makes VITL unique
- VITL's 2026 marketplace unifies prescriptions, pricing, and delivery for cash-pay clinics.
- SignalFire's March 26, 2026 backing validates VITL's focused workflow wedge.
- Over 630 clinics and 1,000 prescribers create network effects for pharmacies and buyers.
Help us improve and share your feedback! Did you find this helpful?